Melanoma genomes contain thousands of alterations including: mutations, copy number alterations, structural aberrations, and methylation changes. The bulk of this variation is stochastic and functionally neutral, with only a small minority representing "drivers" that contribute to the genesis and maintenance of tumors. Drivers are often directly or inversely correlated across tumors, reflecting the molecular and regulatory signaling pathways in which they operate. Here, a profile of genetic and epigenetic drivers in 110 human melanoma cell lines was generated and searched for non-random distribution patterns. Statistically significant mutual exclusivity was revealed among components of each of the p16
Introduction
Melanoma develops from pigment-producing melanocytic cells and is the most aggressive form of skin cancer, causing nearly 50,000 deaths worldwide each year. The incidence of melanoma has increased markedly over the past 50 years and continues to increase in many Western populations. Early detection and surgical excision of the primary tumor can be curative for the majority of patients, but advanced, disseminated forms of the disease are associated with a dismal prognosis (1) . Until recently, the treatment options for metastatic melanoma were limited because of the intrinsic resistance of melanoma cells to conventional forms of anticancer therapy. Significant progress has come from different lines of treatment, including the combination of dacarbazine with ipilimumab (a monoclonal antibody against CTLA-4), the combination of a gp100 peptide vaccine with interleukin-2, monotherapy with trametinib [a mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor], and monotherapy with the BRAF inhibitors vemurafenib (also known as PLX4032) and dabrafenib (reviewed in ref. 2) . In phase III clinical trials, these treatments have all been shown to induce complete or partial tumor regression and increased survival in patients with metastatic melanoma. However, intrinsic or acquired resistance to these treatment options remains a major concern.
A milestone in melanoma research was the discovery of BRAF mutation as a frequent and early event in melanoma development (3) . Extensive work has shown that BRAF mutations (predominantly p.V600E) occurring in more than 50% of melanomas lead to constitutive activation of the RAS-RAF-MEK-ERK signaling pathway (3) and confer a state of "oncogene addiction" on melanoma cells (4, 5) . These findings provided important insights into the biology of melanoma and paved the way for the development of therapeutic small-molecule drugs directed against the BRAF oncogene (reviewed in ref. 2) . The work leading to the discovery of BRAF mutations had been preceded by decadeslong candidate gene approaches, which identified other genes recurrently mutated in melanoma, including NRAS, the CDKN2A locus (also known as INK4A/ARF) and PTEN as some of the most frequent targets (reviewed in ref. 6 ). In addition to these mutational events, other types of molecular alteration have been shown to contribute to melanoma development and progression, including gains of the KIT, MITF, CCND1, and MYC proto-oncogenes and transcriptional silencing of tumor suppressors by promoter hypermethylation (reviewed in ref. 6) .
Data from recent whole-genome or -exome sequencing of melanomas (7) (8) (9) (10) (11) (12) , together with genome-wide studies of copy number variations (13) (14) (15) and DNA methylation changes (16) , have added new layers of complexity to our understanding of the melanoma genome. An important challenge arising from these studies is to identify "driver" events that contribute to melanoma genesis and maintenance, and to distinguish them from functionally neutral "passenger" events. Another challenge is to identify the molecular signaling pathways that are perturbed by driver events. One increasingly used approach to address these challenges is mutual exclusivity analysis. The rationale for this approach is that, although the patterns of genomic alterations in individual tumors are exceedingly diverse and complex, drivers will tend to cluster within a limited number of biologic pathways that are essential for the tumorigenic process (17) . Once a component of a pathway becomes altered through a specific genomic alteration and confers a selective advantage on the tumor cell, second hits in the same pathway will provide no additional advantage and thus will be less likely to accumulate. The consequences of such selection processes are that two hits in the same pathway rarely occur in the same tumor, and that different events within a pathway are inversely correlated across tumors.
Genomic analyses of melanoma have shown mutual exclusivity between BRAF V600E and NRAS mutations, both leading to activation of the RAS-RAF-MEK-ERK pathway (3), between NRAS mutations and inactivating events in PTEN, both leading to activation of the PI3K-AKT pathway (18) , and among mutations in genes encoding components of the p16
INK4A -CDK4-RB senescence barrier (19) . Less is known about the functional significance of other, less frequent alterations. Moreover, integrated analyses of the various types of genome alterations, including copy number variations and DNA-methylation changes, have not been conducted. Here, we have examined the status of known genetic and epigenetic drivers in 110 human melanoma cell lines and assessed their pairwise relationships. This approach confirmed the examples of mutual exclusivity described earlier and further uncovered an inverse correlation between epigenetic silencing of the retinoic acid receptor b (RARb) and genetic inactivation of the melanoma suppressor, p14
ARF . Functional studies in melanocyte and melanoma models suggest that p14 ARF is a downstream target of RARb signaling, and that the status of RARb and p14 ARF in individual melanomas may predict the response to treatment with retinoic acid, the biologically active form of vitamin A.
Materials and Methods

Cells and reagents
Melanoma cell lines were obtained from The European Searchable Tumour Line Database (ESTDAB; http://www. ebi.ac.uk/ipd/estdab) and maintained in RPMI-1640 medium containing 10% FBS and antibiotics at 37 C and 5% CO 2 . The 110 cell lines used in this study were previously characterized for surface markers and tumor-associated antigens, and were DNA fingerprinted to control for duplication and cross-contamination (20) . Primary human melanocytes were obtained from Invitrogen and maintained in Medium 254 containing human melanocyte growth supplement (Invitrogen) at 37 C and 5% CO 2 . All-trans retinoic acid (ATRA) and 5-aza-2 0 -deoxycytidine were purchased from Sigma-Aldrich. LE135 was purchased from Santa Cruz Biotechnology.
Mutations and homozygous deletions
Genomic DNA from melanoma cell lines was isolated using standard procedures. Sequence analysis of CDKN2A was conducted as described previously (21) . Pyrosequencing of the BRAF c.1799T>A mutation was conducted using the PyroMark Q24 platform (Qiagen) and previously described primers (22) . Mutation analysis of BRAF (exons 11 and 15), NRAS (exons 2 and 3), KIT (exons 9, 11, 13, and 17), PIK3CA (exons 9 and 20), PIK3R1 (exon 9, 10, and 12), IDH1 (exon 4), FGFR1 (exon 7), GNAQ (exon 5), TP53 (exons 4-9), CTNNB1 (exon 3), CDK4 (exon 2), RB1 (exons , and PTEN (exons 1-9) was conducted using a combination of PCR and denaturing gradient gel electrophoresis followed by direct sequence analysis. Primers are listed in Supplementary Table S5 . Analysis of RB1 mutations was restricted to cell lines with wild-type CDKN2A and CDK4. Homozygous CDKN2A and PTEN deletions were determined as described previously (23, 24) .
Copy number assessment
Copy numbers of MITF, MYC, AKT3, CDK4, and CCND1 were determined by quantitative PCR (qPCR) using the LightCycler 2.0 instrument (Roche) and the FastStart DNA Master PLUS SYBR Green I Kit (Roche). The LINE-1 retrotransposon was used as a reference gene for all copy number analyses. A mixture of DNA from 6 human healthy donors was used as a diploid control. Copy number gain was defined as a relative copy number of ! 4. Primer sequences and assay conditions are listed in Supplementary Table S5 .
Bisulfite treatment and methylation analysis
Genomic DNA (500 ng) was bisulfite-converted according to the standard procedures (25) 
Quantitative reverse transcription PCR
Total RNA was isolated from cells using the RNeasy Kit (Qiagen) and quantified using a NanoDrop spectrophotometer (NanoDrop Technology, Inc.). Only RNA samples with an A260/A280 ratio of 1.8 or higher were used. Reverse transcription was conducted in reactions containing 5 mg of total RNA, oligo(dT) and random hexamers as primers and SuperScript III reverse transcriptase (Invitrogen). Quantitative reverse transcription PCR (qRT-PCR) was conducted using the Roche LightCycler 2.0 and the FastStart DNA Master PLUS SYBR Green I Kit (Roche). Primer sequences and assay conditions are listed in Supplementary Table S5 .
Immunoblotting
Cytoplasmic and nuclear extracts were fractionated using the NE-PER Nuclear and Cytoplasmic Extraction Reagent Kit (Pierce) and analyzed independently. Protein concentration was measured using the Coomassie Plus Protein Assay Reagent (Pierce). p14 ARF expression was analyzed by 12% NuPAGE gels using MES running buffer (Invitrogen). Membranes were incubated overnight with 2 mg/mL antip14 ARF antibody (Clone 14P03; Labvision) followed by 2 hours of incubation at room temperature.
Transfection and RNA interference
Normal human melanocytes were transfected using the Amaxa nucleofector program U-024 as recommended by the manufacturer. To obtain effective transient RNA interference, melanocytes were transfected twice using 1 mmol/L ON-TARGETplus SMARTpool siRNA to RARb (Dharmacon). ON-TARGETplus siCONTROL Nontargeting si-RNA (Dharmacon) was used as control.
p14
ARF -depleted melanocytes Human melanocytes stably expressing short hairpin RNA (shRNA) targeting CDKN2A will be described in detail elsewhere (Christensen and Guldberg, manuscript in preparation). In brief, melanocytes were transfected with pSuper plasmids containing resistance to G418 (5), and two independent cultures of stable transfectants were generated: HEM-1, which expresses shRNA to a target sequence within CDKN2A exon 2, and HEM-2, which expresses shRNA to a target within CDKN2A exon 1a and has spontaneously lost p14 ARF . Both cultures were maintained in Medium 254 containing human melanocyte growth supplement (Invitrogen), stem cell factor (100 ng/mL; Stratmann Biotech), and endothelin-1 (10 ng/mL; Sigma-Aldrich).
Senescence-associated b-galactosidase assay Cellular senescence was assessed by using the Senescence b-Galactosidase Staining Kit (Cell Signaling Technology) according to the manufacturer's instructions. Senescenceassociated b-galactosidase (SA-b-Gal)-positive cells were identified by their blue-green cytoplamatic staining under Â200 magnification and a total of at least 70 cells were counted from 10 random fields in each experiment. All microscopic fields were scored independently by 2 persons for determination of the mean percentage of positively stained cells.
Growth rates
Cells were seeded at low density in 25 cm 2 flasks and allowed to attach overnight. The next day, the cells were incubated with 10 mmol/L ATRA or vehicle [dimethyl sulfoxide (DMSO)]. Media was replaced every second day for 16 days when control population treated with vehicle reached confluence. Cells were counted with Trypan blue exclusion at day 0, 4, 8, 12, and 16.
Growth inhibition assays
Cells were seeded into 24-well plates (1.5-2.5 Â 10 3 cells/ well) and allowed to attach overnight. The medium was then replaced with 10 mmol/L ATRA (Sigma) or vehicle (DMSO) and grown in the presence or absence of the drug for 14 to 19 days. Each cell line was fixed at the same time and stained with crystal violet. Crystal violet was subsequently extracted and the absorbance was read at 595 nm in a microtiter plate spectrophotometer. Relative absorbance was normalized to the control cells treated with vehicle.
Cell proliferation
Bromodeoxyuridine (BrdUrd) incorporation was determined using the BrdU Cell Proliferation Assay Kit (Cell Signaling). In brief, cells were seeded in a 96-well format (2 Â 10 3 cells/well) and cultured for 24 hours in the presence of 10 mmol/L BrdUrd. Cells were fixed, denaturated, and reacted with detection antibody solution for 1 hour and horseradish peroxidase (HRP)-conjugated secondary antibody for 30 minutes. 3,3 0 ,5,5 0 -Tetramethylbenzidine (TMB) substrate was added for 25 minutes, and absorbance was measured at 450 nm.
Cell-cycle analysis
Cell-cycle analysis was conducted by flow cytometry (FACSVerse BD and FACSDiva BD). Briefly, 10 6 cells were trypsinized, fixed in 70% ethanol, washed and resuspended in PBS containing 10 mg/mL propidium iodide (Sigma) and 1 mg/mL RNase (Sigma). A total of 20,000 events were collected per sample and cell-cycle profiles were obtained using the FlowJo V10 software. When examining the cellcycle distribution, sub-G 1 and polyploid cells were excluded from the analysis. G 1 -, S-, and G 2 -phase gates were applied to histograms by manually defined distribution peaks.
Statistical analysis
All calculations were carried out in R (http://www.r-project.org). Mutation, deletion, amplification, and promoter hypermethylation events were transformed into dichotomous variables and analyzed for correlations using the Pearson correlation coefficient. The significance level of these correlations was determined using the Fisher exact test.
Results
Genetic and epigenetic drivers in human melanoma cell lines DNA from 110 unrelated melanoma cell lines was systematically examined for specific mutation, deletion, amplification, and promoter hypermethylation events. A list of genes and the frequencies and types of alterations are shown in Fig. 1 , and detailed information is provided in Supplementary Tables S1-S4. A total of 646 alterations were identified in this series of melanoma cell lines, with an average of 5.9 (range, 0-10) alterations per cell line. One cell line (ESTDAB-097) carried none of the drivers investigated, and ESTDAB-098 cells carried low copy number gains of CCND1 and MITF as the only changes.
Mutations were identified in known hot-spot regions of 10 different proto-oncogenes ( Fig. 1 ; Supplementary Tables S1 and S2). The most frequent target was BRAF, which harbored mutations in 75 of the cell lines (68%), with p. V600E accounting for 66 of these events (88%). Mutations in NRAS were found in 18 of the cell lines (16%), and 16 of these mutations affected residue Q61. Mutations in the remaining proto-oncogenes were less frequent, affecting
, and residues 464-468 of PIK3R1 (N ¼ 1). The two cell lines harboring GNAQ mutations were established from uveal melanomas, consistent with previous reports showing that GNAQ mutations occur at high rates in this melanoma subtype (27) .
Mutations and/or deletions of the tumor suppressors CDKN2A, PTEN, and TP53 were identified in 93 (85%), 33 (30%), and 26 (24%) of the cell lines, respectively ( Fig. 1 and Supplementary Table S1 ). The majority of CDKN2A alterations were predicted to affect both p16 INK4A and p14 ARF ; however, subsets of alterations were specific for either protein, including deletion (N ¼ 2) or mutation (N ¼ 1) of exon 1a (specific for p16 INK4A ), deletion of exon 1b (specific for p14 ARF ; N ¼ 1), and missense mutations in exon 2 potentially affecting either p16
. One specific CDKN2A mutation affecting both p16 INK4A and p14 ARF (p.R80X/p.P94L) was found in five of the cell lines. In the following, the gene symbols INK4A and ARF will be used to specify, when appropriate, whether CDKN2A alterations have a predicted effect on p16 INK4A and p14 ARF , respectively. A total of 73 copy number gains were identified, with frequencies of 25% for CCND1, 19% for MITF, 15% for MYC, 5% for AKT3, and 3% for CDK4 ( Fig. 1 and Supplementary Table S3 ). None of the AKT3 gains was greater than 5. A total of 255 promoter hypermethylation events were identified, with frequencies of 56% for IGFBP7, 55% for RASSF1A, 53% for PYCARD, 45% for RARB, 13% for APC, and 11% for INK4A ( Fig. 1 and Supplementary Table  S4 ). Overall, 99 of the cell lines (90%) were hypermethylated in one or more of the six promoter regions, 77 (70%) had two or more hypermethylated genes, and 50 (45%) had three or more hypermethylated genes.
Pathway analysis and pairwise associations Table 1 lists the genomic alterations grouped according to known molecular pathways. Genes encoding components of the RAS-RAF-MEK-ERK pathway were altered in 86% of the cell lines, the majority of which (96%) carried mutations in BRAF and/or NRAS. Consistent with previous evidence showing that activating mutations in KIT, FGFR1, and GNAQ can activate the RAS-RAF-MEK-ERK pathway, cell lines carrying mutations in either of these genes carried wild-type copies of BRAF and NRAS. The p16
INK4A
-CDK4-RB senescence barrier was affected in 91% of the cell lines, either through inactivating INK4A events, RB1 mutations and/or amplification, or mutation of CDK4; genetic events affecting the PI3K-AKT signaling pathway were found in 53% of the cell lines, with alterations in PTEN and NRAS accounting for 86% these events; and the p53-p14 ARF axis was affected in 79% of the cell lines, either through TP53 mutation, ARF mutation/deletion, or both.
For genes that were altered in at least four of the melanoma cell lines, we conducted pairwise comparisons using the Pearson correlation coefficient ( Table 2 ). Negative associations were found between BRAF and NRAS mutations, which only coexisted in two cell lines harboring non-p. V600E BRAF mutations (P ¼
À5 ), and NRAS and PTEN alterations (P ¼ 0.012). PTEN alterations correlated positively with BRAF mutations (P ¼ 9.6 Â 10 À5 ). Among other statistically significant direct and inverse correlations (see Table 2 ), one particularly interesting finding was an inverse correlation between CDNK2A alterations and hypermethylation of the RARB promoter. Notably, this association was much stronger for ARF alterations (P ¼ 2.7 Â 10 À5 ) than for INK4A alterations (P ¼ 0.025). Of the 110 cell lines, 52 harbored mutation or deletion of ARF and wildtype RARB (47%), 26 had RARB promoter hypermethylation and wild-type ARF (24%), and 23 harbored alteration of both genes (21%). Only nine cell lines carried both wildtype ARF and RARB (8%). Notably, while RARB hypermethylation was under-represented in cell lines with ARF alterations, it was over-represented in cell lines carrying CDKN2A alterations that specifically target the expression or function of p16 INK4A , for example, INK4A promoter hypermethylation events and mutations and deletions affecting exon 1a (14 of 18; x 2 test; P < 0.05).
Retinoic acid induces p14 ARF expression in human melanocytes via RARb
Previous studies have shown that human epidermal melanocytes are growth inhibited by ATRA (28, 29) and that the expression of the RARb2 isoform [the predominant receptor mediating the proliferation inhibitory effects of ATRA (30)] is often lost in melanomas due to promoter hypermethylation. As our genomic data suggested a link between RARB and ARF in melanoma, we conducted a series of experiments to address whether p14 ARF is a downstream target gene of the RARb-mediated signaling cascade. We first asked whether the expression of p14 ARF in melanocytes is altered upon short-term exposure to ATRA. In two independent cultures of primary human melanocytes, treatment with 10 mmol/L ATRA for 48 hours led to upregulation of RARb2, a known direct target of retinoic acid (ref. 31 ; and data not shown). Interestingly, in the same cells, ATRA also increased the expression of p14 ARF at both the mRNA and protein levels in a dose-dependent manner ( Fig. 2A) . To examine whether this ability of ATRA to induce p14 ARF expression is mediated via RARb, we cultured melanocytes in the presence or absence of the RARb antagonist LE135 (32) . As shown in Fig. 2B , LE135 effectively blocked the ATRA-induced expression of p14 ARF . As LE135 may also act as an antagonist of RARa, we extended our analysis by transiently transfecting normal human melanocytes with either siRNAs targeting RARb or control siRNAs. As shown in Fig. 2C , knockdown of RARb resulted in a more than 60% reduction in the steady-state expression levels of p14 ARF 48 hours posttransfection. Collectively, these data suggest that RARb signaling contributes to the regulation of p14 ARF expression in melanocytes.
Cellular responses to ATRA in normal and p14
ARF -depleted melanocytes
To characterize in greater detail the cellular response of normal melanocytes to ATRA, we first assessed the effects on cell proliferation by measuring the rate of DNA synthesis. As shown in Fig. 3A , BrdUrd incorporation was reduced by 50% after 10 days of growth in the presence of ATRA. Furthermore, this effect could be rescued by LE135, suggesting that the growth-inhibitory effects of ATRA are mediated via RARb. To determine the effect on cell-cycle distribution, melanocytes were treated with ATRA for 10 days and analyzed by fluorescence-activated cell sorting (FACS) analysis. These experiments showed an accumulation of cells in G 1 -phase of the cell cycle and a corresponding decrease in the fraction of cells in S-and G 2 -phases (Fig. 3B) .
We next measured the activity of SA-b-Gal, a hallmark of senescence (33) . Treatment of two independent cultures of melanocytes with ATRA for 2 weeks increased the fraction of SA-b-Gal-positive cells by 300% to 600% (Fig. 3C) . As senescence induced by oncogenic stimuli has been shown to be accompanied by higher p14 ARF expression in some cell types (34) and as ATRA increased the expression of p14 ARF in normal human melanocytes ( Fig. 2A) , we investigated the role of p14 ARF in mediating ATRA-induced growth arrest. To this end, we used two independent lines of melanocytes that express shRNAs against CDKN2A sequences and express low levels of p14 ARF (HEM-1 and -2; see Materials and Methods). When SA-b-Gal was used as a surrogate marker of senescence, the response to ATRA was significantly reduced in Fig. 3C and D) . In conclusion, treatment of normal human melanocytes with ATRA is associated with loss of proliferative activity, G 1 arrest, and increased activity of SA-b-Gal, and this response may at least in part depend on p14 ARF .
ATRA induces irreversible G 1 arrest in melanoma cells with an intact RARb-p14
ARF axis The majority of human melanomas are inherently resistant or weakly sensitive to ATRA (35) . Part of this resistance can be explained by epigenetic silencing of RARb2, which is found in 20% to 70% of melanoma cell lines (reviewed in ref. 6 ; and this study). However, resistance mechanisms in melanoma cells expressing RARb2 have not been elucidated. Given the strong genetic and functional links between RARb and p14 ARF , we addressed whether the status of RARB and ARF could predict the sensitivity of melanoma to ATRA. Specifically, we asked whether melanoma cells with an intact RARb-p14 ARF axis are sensitive to ATRA. From the nine melanoma cell lines identified with an unmethylated RARB promoter and wild-type ARF, we excluded ESTDAB-097 and ESTDAB-098 as they grew slowly in culture and carried no melanoma-specific genome alterations, and ESTDAB-179, which did not express p14 ARF even though no CDKN2A alterations were identified. All the remaining six cell lines expressed p14 ARF and RARb2 mRNA (data not shown). Consistent with the data obtained in melanocytes ( Fig. 2A) , treatment with ATRA increased the expression levels of p14 ARF in these cell lines by 1.5-to 2.5-fold (data not shown). Interestingly, all six cell lines responded to treatment with ATRA (Fig. 4) . Two of these lines harbored INK4A alterations, one harbored a TP53 mutation, and one harbored defects in both genes, suggesting that p16 INK4A and p53 are dispensable for execution of ATRA-induced growth /L) . B, FACS analysis showing representative cell-cycle profiles of normal human melanocytes cultured for 10 days in the presence or absence of ATRA (10 mmol/L). C, ATRA-induced senescence in two cultures of normal human melanocytes (WT-1 and -2) and two independent pools of melanocytes expressing shRNAs against CDKN2A sequences (HEM-1 and -2). Cells were treated with ATRA (10 mmol/L) for 2 weeks, and the number of senescent cells was determined by SA-b-Gal positivity. Columns represent percentage of SA-b-Gal-positive cells. D, the same data as in (C), but with the increase in senescence in normal melanocytes set at 100%. Statistical analysis was conducted using a paired t test. Ã , P < 0.05; ns, nonsignificant.
In the context of our findings, a pertinent question is whether restoration of RARb expression is able to restore ATRA sensitivity in melanoma cells. To address this question, we first treated two melanoma cell lines with RARB promoter hypermethylation and wild-type ARF with the DNA-hypomethylating agent 5-aza-2 0 -deoxycytidine (5-aza-CdR). As shown in Fig. 4D , treatment with 1 mmol/ L 5-aza-CdR for 4 days reactivated RARb2 mRNA expression in both cell lines. Furthermore, in contrast to untreated cells, the growth of 5-aza-CdR-treated cells was significantly inhibited by ATRA, suggesting that derepression of RARb2 can restore ATRA sensitivity (Fig. 4E) .
We made several attempts to stably deplete RARb-and p14 ARF -expressing melanoma cell lines of p14 ARF to be able to study more directly the role of this protein in long-term cellular repsonses to ATRA. However, although we used the same shRNA vectors that efficiently knocked down p14 ARF in normal melanocytes ( Fig. 2; and data not shown) and stable clones were readily generated with the empty vector, we were unable to generate clones expressing shRNA vectors targeting p14 ARF in any of these six cell lines (data not shown). Cell-cycle analysis of RARb-and p14 ARF -expressing melanoma cells treated with ATRA showed a decrease in the fraction of cells in S-and G 2 -phases of the cell cycle and an increase in the fraction of cells in G 1 -phase (Fig. 5A) . Analysis of the sub-G 1 fraction did not show an increase in the number of apoptotic cells in ATRA-treated cultures (data not shown). After 3 weeks of growth in the presence of ATRA, BrdUrd incorporation was reduced by 50% (Fig. 5A) , similar to what was observed in primary melanocytes ( Fig. 2A) . Cells were then released and cultured for 1 week in medium without exogenously added ATRA. As shown in Fig. 5B , BrdUrd incorporation was not increased after the release. Together, these results suggest that ATRA induces irreversible G 1 arrest in melanoma lines with an intact RARb-p14 ARF axis.
Discussion
We have generated a profile of genetic and epigenetic drivers in human melanoma-derived cell lines and searched for pairwise associations across all genes to identify possible functional interplays. The use of established cell lines for this type of approach has both advantages and disadvantages, which should be taken into account when interpreting our data. A major advantage of using cell line DNA as a template is that some genomic changes, particularly homozygous deletions and copy number gains, can be determined with greater accuracy as they will not be masked by contaminating normal tissue. Although cell lines may contain genomic artifacts introduced as a result of cell culturing, previous studies have shown that cell lines usually are representative of the tumors from which they originate (36) . The frequencies of genome alterations found in our study are generally higher than, but still compatible with the frequencies observed in melanoma biopsies (6) . A potential limitation of studies based on cancer cell lines, including ours, is that they are confounded by a bias in favor of tumors that are able to grow under standard culture conditions and thus may have specific cellular properties and genomic changes. Accordingly, the collection of melanoma cell lines used in our study, although relatively large in number, may not be clinically representative. Previous work on smaller collections of melanoma cell lines (37, 38) and uncultured melanomas have found a number of driver associations, which we confirmed in this study, including negative associations between BRAF and NRAS mutations, CDK4 and INK4A alterations, and NRAS and PTEN alterations, and a positive correlation between PTEN and BRAF alterations. The functional implications of these associations have all been corroborated in various experimental models (3, 19, 39) . In addition to the above associations, a previous study (38) suggested a negative association between ARF (exon 1b) and TP53 alterations, consistent with the known role of p14 ARF as a positive regulator of p53 (34) and with the consensus view that the relatively low frequency of TP53 mutations in melanoma can be explained by a high frequency of inactivating ARF events. An association between ARF and TP53 alterations did not reach statistical significance in our study, and thus it remains unclear whether p14 ARF and p53 operate in the same or different molecular pathways in melanoma. In support of the latter, previous work has shown that p19
Arf (the mouse homolog of p14 ARF ) can function as a melanoma suppressor by inducing p53-independent senescence (40) .
As the most important novel finding in our study, we uncovered a strong inverse correlation between hypermethylation of the RARB promoter and ARF alterations. This association was particularly relevant as little is known about the melanoma-suppressive properties of RARb, and as genomic alterations of other core components of the retinoic acid signaling pathway have not been described in melanoma. To corroborate the link between RARb and p14 ARF suggested by the genomic data, we first investigated whether the regulation of p14 ARF expression was influenced by the changes in RARb expression or ligand concentrations. In cultures of normal human melanocytes, steady-state levels of p14 ARF were increased at both the mRNA and protein level upon short-term exposure to ATRA, whereas they were reduced in response to depletion or chemical inhibition of RARb. These findings are consistent with an important role of RARb signaling in the regulation of p14 ARF expression in melanocytes and would, to our knowledge, identify retinoic acid as the first naturally occurring inducer of p14 ARF . Previous studies have shown that p14 ARF expression can be induced by hyperproliferative stimuli such as those elicited by the Myc and E1A oncogenes (34), providing an explanation for the tumor-specific properties and expression patterns of p14 ARF . Several reports have suggested that p14 ARF and p19 Arf are not expressed in most normal cells, including cultured human melanocytes (41) . However, our data show that ATRA can induce the expression of p14 ARF in normal melanocytes in the nanomolar range, that is, at concentrations similar to the concentrations of retinoids in normal epidermis (42) . Considering the important role of retinoids and RARs in embryonic development and cellular differentiation (43) , p14 ARF expression in melanocytes may depend on the differentiation state of these cells, which is, at least in part, controlled by retinoic acid (44) . A functional role of p14 ARF in normal differentiated melanocytes remains unknown.
The implication of p14 ARF as a melanoma suppressor has been controversial and notoriously difficult to study, primarily due to the unusual structure of the CDKN2A locus, which encodes p14 ARF and p16 INK4A in different reading frames (34) . Although a critical role for p16
INK4A in replicative and oncogene-induced melanocyte senescence has been well documented both in vitro and in vivo (33, 45, 46) , these studies have provided little insight into a possible role of p14 ARF . Studies of cancer-associated CDKN2A mutation patterns have suggested that exon 2 mutations preferentially target p16
INK4A function (38) and thus that p14 ARF is coincidentally inactivated in a high proportion of melanomas due to the strong selection pressure against p16 INK4A . To better understand the association between RARb signaling and the melanoma-suppressive properties of the CDKN2A locus, we conducted a series of experiments in the settings of melanocytes and melanoma cells. Consistent with previous work (28, 29) , we showed that ATRA could induce senescence in normal human melanocytes. This response was dependent on CDKN2A, as senescence was less pronounced in cells depleted of p14 ARF and p16
INK4A
. Furthermore, while melanoma cell lines are generally resistant to retinoids (35) , cell lines with wild-type copies of RARB and ARF responded to treatment with ATRA. Importantly, some of the ATRA-responsive cell lines harbored INK4A and/or TP53 alterations, suggesting that the response to ATRA is independent of the functions of p16 INK4A and p53. p14
ARF is lost in a great proportion of melanomas and is considered as a bona fide tumor suppressor. In this context, it was unexpected that stable depletion of p14 ARF was not compatible with continued growth of melanoma cells with an intact RARb-p14 ARF axis. This finding may suggest that p14 ARF is essential for cell survival in some cases of melanoma and thus represents an example of nononcogene addiction, as has been described for a number of genes required for cancer cells to tolerate cellular stresses (47) . Despite this unresolved issue, the collected data from our genetic and functional studies suggest that RARb and p14 ARF operate in the same molecular pathway, and that the melanoma-suppressive function of p14 ARF may be related to its role in this pathway.
Our findings may have clinical implications. Topical treatment with retinoic acid has been found to be effective in dysplastic nevi (48) and resulted in tumor regression in 2 patients with cutaneous metastatic melanoma (49) . However, the clinical activity of retinoids for systemic treatment of melanoma is limited with only few patients showing a positive response (50) (51) (52) . Currently, no predictive markers of ATRA responsiveness are available for clinical use. Our data showing that melanoma cell lines with wild-type copies of RARB and ARF respond to treatment with ATRA suggest that the status of these genes identifies a group of patients who may benefit from therapies including retinoids.
In conclusion, our data suggest that RARb and p14 ARF may be linked in a signaling pathway that is operating in melanocytic cells and is lost in the majority of melanomas. This is an example of how integrated genomic analysis of cancer may be used to map individual drivers to specific molecular pathways and to reveal previously unrecognized molecular cross-talk. The set of melanoma drivers examined here is not exhaustive. Indeed, recent sequencing studies have identified several additional putative melanoma drivers, albeit at low frequency (<10%; refs. 7-12). Moreover, our understanding of the importance of the multiple methylation changes present in melanoma genomes is still at an early stage. The collection of melanoma cell lines characterized here may be useful for further unraveling the hierarchy of driver genes and molecular pathways in melanoma. As exemplified by the identification of a subset of melanomas that respond to retinoic acid, these cell lines may also be of value for studying the genomic basis of therapeutic sensitivity and resistance in melanoma and for identifying new targets for intervention. With the realization that intrinsic and acquired resistance is an inherent problem of current melanoma treatment options (2), the need for developing new rational treatment regimens that can effectively control this malignancy is urgent.
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